Sûreté et gouvernance des risques
Are European biotechnology companies sufficiently protected?
Jean-Christophe Marcoux, consultant at IMS Health, is addressing some of the key challenges European biotechs face today, and he does it from an infowar perspective. This gives a great opportunity to understand what’s at stake, and it provides key insights on strategies that can be used. It’s also a call for action to all European players willing and able to preserve patients’ interests.
19 juin 2015